New pill aims to tame dangerous phosphate in kidney patients
NCT ID NCT07285304
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 study tests a new drug called TS-172 in 300 adults on hemodialysis who have high phosphate levels. Participants take the pill daily for up to a year to see if it safely and effectively controls phosphate. The goal is to offer a better treatment option for a common complication of kidney failure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TS-172 (a phosphate binder taken orally)
What this could lead to
If it works, this could offer a new option to help dialysis patients better manage high phosphate levels, reducing complications.
What could go wrong
This is a long-term safety study, so it may not show clear benefit. Side effects or lack of effectiveness could limit its use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Taisho Pharmaceutical Co., Ltd selected site
RECRUITINGTokyo, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••